290 citations
,
August 2021 in “Clinical Reviews in Allergy & Immunology” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
4 citations
,
January 2020 in “PubMed” This source reports that JAK inhibitors, such as ruxolitinib, baricitinib, and tofacitinib, have led to hair regrowth in alopecia areata patients and animal models, but their long-term safety and effectiveness remain uncertain, with ongoing trials to further investigate these factors.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” This review discusses the potential of Janus Kinase inhibitors for treating alopecia areata and other forms of alopecia, highlighting the need for further research on their long-term safety and optimal formulation.
9 citations
,
December 2017 in “The Journal of Allergy and Clinical Immunology” This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
1 citations
,
November 2017 in “Dermatologic therapy” This article discusses Janus kinase inhibitors as a promising future treatment for alopecia areata but does not present new research findings.
99 citations
,
July 2017 in “Clinical Reviews in Allergy & Immunology” This review noted that alopecia areata is an autoimmune disease impacting hair follicles and offered insights into its complex pathogenesis involving immune responses, while highlighting ongoing research into new treatments such as Janus kinase inhibitors and other immunomodulatory drugs.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, distinct molecular mechanisms of action were identified for three drugs used in alopecia areata clinical trials, providing insights for precision medicine and treatment selection.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
2 citations
,
March 2015 in “Expert opinion on orphan drugs” This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.
70 citations
,
February 2015 in “Expert Opinion on Drug Discovery” This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.
17 citations
,
September 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that anthralin and mechlorethamine were the most effective therapies among those tested in AA-affected rodent models, providing a basis for further analysis of their mechanisms in Alopecia Areata.
48 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” This review assesses the effectiveness of various alopecia areata treatments and concludes that only contact sensitizers like diphenylcyclopropenone and squaric acid dibutylester have shown efficacy in evidence-based studies, but it reports no new clinical results.